down arrow

Inari Medical, Inc.

  • Market Cap: Small Cap
  • Industry: Medical Specialties
  • ISIN: US45332Y1091
USD
79.97
0.00 (0.00%)

Feb 20

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

40.2079.99
Valuation
Technical
Day's Volume

CASH

0

Shareholding (Sep 2024)

FII

16.91%

Held by 143 FIIs

DII

15.37%

Held by 71 DIIs

Promoter

5.57%

How big is Inari Medical, Inc.?

22-Jun-2025

As of Feb 20, Inari Medical, Inc. has a market capitalization of $4.68 billion, with net sales of $574.49 million and a net profit of -$78.59 million over the last four quarters. The company's shareholder's funds are $464.91 million, and total assets amount to $674.24 million.

Market Cap: As of Feb 20, Inari Medical, Inc. has a market capitalization of 4,683.33 million, categorizing it as a Small Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Inari Medical reported net sales of 574.49 million and a net profit of -78.59 million.<BR><BR>Balance Sheet Snapshot: As of Dec 23, the company's shareholder's funds amounted to 464.91 million, while total assets were reported at 674.24 million.

Read More

What does Inari Medical, Inc. do?

22-Jun-2025

Inari Medical, Inc. is a medical device company specializing in treatments for venous diseases, with recent net sales of $153 million and a net loss of $18 million. It has a market cap of approximately $4.68 billion and operates in the small-cap sector.

Overview:<BR>Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat venous diseases, operating within the Medical Specialties industry and classified as a small-cap company.<BR><BR>Financial Snapshot:<BR>- Most recent Net Sales: 153 Million (Quarterly Results - Sep 2024)<BR>- Most recent Net Profit: -18 Million (Quarterly Results - Sep 2024)<BR>- Market-cap: USD 4,683.33 Million (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 97.97%<BR>- Debt Equity: -0.25<BR>- Return on Equity: -11.07%<BR>- Price to Book: 10.77<BR><BR>Contact Details:<BR>- Address: 9 Parker, Suite 100, IRVINE CA : 92618<BR>- Tel: 1 949 9234747<BR>- Website: https://www.inarimedical.com

Read More

Should I buy, sell or hold Inari Medical, Inc.?

22-Jun-2025

Who are in the management team of Inari Medical, Inc.?

22-Jun-2025

As of March 2022, the management team of Inari Medical, Inc. includes Mr. Donald Milder (Independent Chairman), Mr. William Hoffman (CEO), and several independent directors: Ms. Cynthia Lucchese, Mr. Kirk Nielsen, Mr. Geoff Pardo, and Dr. Jonathan Root. They oversee the company's strategic direction and operations.

As of March 2022, the management team of Inari Medical, Inc. includes the following individuals:<BR><BR>- Mr. Donald Milder, Independent Chairman of the Board<BR>- Mr. William Hoffman, President, Chief Executive Officer, and Director<BR>- Ms. Cynthia Lucchese, Independent Director<BR>- Mr. Kirk Nielsen, Independent Director<BR>- Mr. Geoff Pardo, Independent Director<BR>- Dr. Jonathan Root, Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor Management Efficiency with a low ROE of 2.59%

  • The company has been able to generate a Return on Equity (avg) of 2.59% signifying low profitability per unit of shareholders funds
2

The company has declared negative results for the last 3 consecutive quarters

3

Risky - Not traded in last 10 days

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Medical Specialties

stock-summary
Market cap

USD 4,683 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

97.97%

stock-summary
Debt Equity

-0.25

stock-summary
Return on Equity

-11.07%

stock-summary
Price to Book

10.77

Revenue and Profits:
Net Sales:
153 Million
(Quarterly Results - Sep 2024)
Net Profit:
-18 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
63.2%
0%
63.2%
6 Months
62.74%
0%
62.74%
1 Year
37.62%
0%
37.62%
2 Years
42.8%
0%
42.8%
3 Years
8.27%
0%
8.27%
4 Years
-32.62%
0%
-32.62%
5 Years
0%
0%
0.0%

Inari Medical, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
50.85%
EBIT Growth (5y)
-223.69%
EBIT to Interest (avg)
-7.30
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.25
Sales to Capital Employed (avg)
1.04
Tax Ratio
47.28%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
16.11%
ROE (avg)
2.59%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
10.77
EV to EBIT
-142.76
EV to EBITDA
-302.09
EV to Capital Employed
14.08
EV to Sales
7.96
PEG Ratio
NA
Dividend Yield
97.97%
ROCE (Latest)
-9.87%
ROE (Latest)
-11.07%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Sep 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 84 Schemes (62.07%)

Foreign Institutions

Held by 143 Foreign Institutions (16.91%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2024 is 21.36% vs 31.39% in Sep 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2024 is -675.00% vs 131.37% in Sep 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'24",
        "Sep'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "153.40",
          "val2": "126.40",
          "chgp": "21.36%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.30",
          "val2": "4.30",
          "chgp": "-130.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-18.40",
          "val2": "3.20",
          "chgp": "-675.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-43.40%",
          "val2": "16.70%",
          "chgp": "-6.01%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 28.71% vs 38.45% in Dec 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 94.54% vs -398.98% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "493.60",
          "val2": "383.50",
          "chgp": "28.71%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "7.10",
          "val2": "-20.50",
          "chgp": "134.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.30",
          "chgp": "-33.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-11.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.60",
          "val2": "-29.30",
          "chgp": "94.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-7.40%",
          "val2": "-73.30%",
          "chgp": "6.59%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'24 - YoYstock-summary
Sep'24
Sep'23
Change(%)
Net Sales
153.40
126.40
21.36%
Operating Profit (PBDIT) excl Other Income
-1.30
4.30
-130.23%
Interest
0.10
0.00
Exceptional Items
-6.90
0.00
Consolidate Net Profit
-18.40
3.20
-675.00%
Operating Profit Margin (Excl OI)
-43.40%
16.70%
-6.01%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Sep 2024 is 21.36% vs 31.39% in Sep 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Sep 2024 is -675.00% vs 131.37% in Sep 2023

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'23stock-summary
Dec'23
Dec'22
Change(%)
Net Sales
493.60
383.50
28.71%
Operating Profit (PBDIT) excl Other Income
7.10
-20.50
134.63%
Interest
0.20
0.30
-33.33%
Exceptional Items
-11.00
0.00
Consolidate Net Profit
-1.60
-29.30
94.54%
Operating Profit Margin (Excl OI)
-7.40%
-73.30%
6.59%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2023 is 28.71% vs 38.45% in Dec 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 94.54% vs -398.98% in Dec 2022

All Annual Resultsstock-summary
stock-summaryCompany CV
About Inari Medical, Inc. stock-summary
stock-summary
Inari Medical, Inc.
Medical Specialties
Inari Medical, Inc. is a commercial-stage medical device company. The Company is focused on developing products to treat venous diseases. The Company’s product offering consists of two minimally-invasive, catheter-based mechanical thrombectomy devices. The Company built two products for the treatment of venous thromboembolism (VTE deep vein thrombosis) and pulmonary embolism (PE). The Company provides two products ClotTriever and FlowTriever. ClotTriever product is Food and Drug Administration (FDA) cleared for the removal of clot from peripheral blood vessels and is used to deep vein thrombosis (DVT). FlowTriever product is thrombectomy system FDA cleared for the treatment of pulmonary embolism (PE). Its product ClotTriever and FlowTriever offer clinical benefits and provides safety to limit effectiveness of thrombolytic drugs and repurposed arterial devices for the treatment of VTE.
Company Coordinates stock-summary
Company Details
9 Parker, Suite 100, Suite 100 , IRVINE CA : 92618
stock-summary
Tel: 1 949 9234747
stock-summary
https://www.inarimedical.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."